Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
72 hedge funds and large institutions have $18M invested in Accelerate Diagnostics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 21 reducing their positions, and 16 closing their positions.
14% less funds holding
Funds holding: 84 → 72 (-12)
29% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 21
56% less capital invested
Capital invested by funds: $41.2M → $18M (-$23.2M)
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
65% less call options, than puts
Call options by funds: $52K | Put options by funds: $148K
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Griffin Asset Management
New York
|
+$1.38M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$543K |
| 3 |
Morgan Stanley
New York
|
+$241K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$88.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
-$684K |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$634K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$544K |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$456K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$446K |
AXDX Hedge Fund Activity: Q4 2022 in Review
72 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2022, worth a combined $18M — down 56% from $41.2M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AXDX and 6 opened new positions — a net loss of 10 holders — while 21 trimmed existing stakes and 15 added.
The largest buyer was Griffin Asset Management, adding an estimated $1.38M. The largest seller was 1492 Capital Management, exiting entirely with an estimated $684K sold.
- 72 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2022, down from 84 in Q3 2022.
- Funds reported $18M of Accelerate Diagnostics stock for Q4 2022, down 56% quarter-over-quarter.
- 6 funds opened new Accelerate Diagnostics positions in Q4 2022 and 16 closed out, a net change of -10 holders.
- The largest Accelerate Diagnostics buyer in Q4 2022 was Griffin Asset Management, an estimated $1.38M added.
- The largest Accelerate Diagnostics seller in Q4 2022 was 1492 Capital Management, an estimated $684K sold.
Based on aggregated 13F filings for Q4 2022.